Table 4.
Median levels of hBD1, hBD2, hBD3 and hBD4 in serum of COVID-19 cases stratified according to characteristics of patients.
| Characteristic | Median (IQR: 25–75%); ng/L |
||||
|---|---|---|---|---|---|
| hBD1 | hBD2 | hBD3 | hBD4 | ||
| Age group | <45 years | 198.0 (151.5–307.3) | 1100 (955–1203) | 1580 (1470–2144) | 4.08 (3.29–5.13) |
| ≥45 years | 204.9 (158.5–238.1) | 1015 (852–1175) | 1532 (1220–1936) | 4.04 (3.32–5.03) | |
| p-value | 0.665 | 0.293 | 0.107 | 0.623 | |
| Gender | Male (N = 76) | 199.4 (157.6–234.8) | 1009 (853–1188) | 1583 (1332–1960) | 4.05 (3.32–4.93) |
| Female (N = 27) | 206.0 (162.8–307.4) | 1071 (954–1185) | 1453 (1142–2020) | 4.04 (3.19–5.79) | |
| p-value | 0.669 | 0.414 | 0.152 | 0.913 | |
| BMI | NOR (N = 28) | 227.4 (160.5–323.6) | 1106 (845–1339) | 1668 (1306–2160) | 4.43 (3.32–5.27) |
| O/O (N = 75) | 196.9 (157.6–229.8) | 1008 (866–1147) | 1532 (1220–1936) | 3.95 (3.26–5.03) | |
| p-value | 0.138 | 0.128 | 0.341 | 0.224 | |
| CHD | Yes (N = 59) | 197.2 (157.6–231.2) | 1053 (921–1189) | 1644 (1297–2050) | 4.18 (3.55–5.26) |
| No (N = 44) | 207.5 (156.8–258.3) | 1012 (844–1180) | 1491 (1152–1893) | 3.88 (3.15–4.81) | |
| p-value | 0.857 | 0.650 | 0.148 | 0.146 | |
BMI: Body mass index; NOR: Normal weight; O/O: Overweight/obese; CHD: Chronic disease; IQR: Interquartile range; hBD: Human β-defensin; p: Probability of Mann-Whitney U test.